FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113018780> ?p ?o ?g. }

• W2113018780 endingPage "2383" @default.
• W2113018780 startingPage "2377" @default.
• W2113018780 abstract "No AccessJournal of UrologyInvestigative Urology1 Dec 2012Diagnostic Potential of Urinary α1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer Virginia Urquidi, Steve Goodison, Shanti Ross, Myron Chang, Yunfeng Dai, and Charles J. Rosser Virginia UrquidiVirginia Urquidi Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience. More articles by this author , Steve GoodisonSteve Goodison Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience. More articles by this author , Shanti RossShanti Ross Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida More articles by this author , Myron ChangMyron Chang Department of Biostatistics, University of Florida, Gainesville, Florida More articles by this author , Yunfeng DaiYunfeng Dai Department of Biostatistics, University of Florida, Gainesville, Florida More articles by this author , and Charles J. RosserCharles J. Rosser Section of Urologic Oncology, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience, Endocare and the Department of Defense. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.07.094AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The ability to reliably diagnose bladder cancer in voided urine samples would be a major advance. Using high throughput technologies, we identified a panel of bladder cancer associated biomarkers with potential clinical usefulness. In this study we tested 4 potential biomarkers for the noninvasive detection of bladder cancer. Materials and Methods: We examined voided urine specimens from 124 patients, including 63 newly diagnosed with bladder cancer and 61 controls. Concentrations of proteins were assessed by enzyme-linked immunosorbent assay, including α1-antitrypsin, apolipoprotein E, osteopontin and pentraxin 3. Data were compared to the results of urinary cytology and the BTA Trak® enzyme-linked immunosorbent assay based bladder cancer detection assay. We used the AUC of ROC curves to compare the usefulness of each biomarker to detect bladder cancer. Results: Urinary levels of α1-antitrypsin, apolipoprotein E and bladder tumor antigen were significantly increased in subjects with bladder cancer. α1-Antitrypsin (AUC 0.9087, 95% CI 0.8555–0.9619) and apolipoprotein E (AUC 0.8987, 95% CI 0.8449–0.9525) were the most accurate biomarkers. The combination of α1-antitrypsin and apolipoprotein E (AUC 0.9399) achieved 91% sensitivity, 89% specificity, and a positive and negative predictive value of 89% and 90%, respectively. Multivariate regression analysis highlighted only apolipoprotein E as an independent predictor of bladder cancer (OR 24.9, 95% CI 4.22–146.7, p = 0.0004). Conclusions: Alone or in combination, α1-antitrypsin and apolipoprotein E show promise for the noninvasive detection of bladder cancer (OR 24.9, 95% CI 4.22–146.7, p = 0.0004). Larger, prospective studies including more low grade, low stage tumors are needed to confirm these results. References 1 : Cancer statistics, 2012. CA Cancer J Clin2012; 62: 10. Google Scholar 2 : Urine cytology of transitional cell neoplasms. Urol Clin North Am1979; 6: 599. Crossref, Medline, Google Scholar 3 : Usefulness of the BTA STAT Test for the diagnosis of bladder cancer. Urology2001; 57: 685. Google Scholar 4 : Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology2010; 77: 154. Google Scholar 5 : Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer2007; 111: 517. Google Scholar 6 : Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev2009; 18: 444. Google Scholar 7 : Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res2007; 6: 2631. Google Scholar 8 : Urinary glycoprotein biomarker discovery for bladder cancer detection using LC-MS/MS and label-free quantification. Clin Cancer Res2011; 17: 3349. Google Scholar 9 : Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology2005; 66: 35. Google Scholar 10 : Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract2004; 21: 4. Google Scholar 11 : AJCC Cancer Staging Manual. American Joint Committee on Cancer, American Cancer Society New York: Springer-Verlag2002. Google Scholar 12 : The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol2005; 13: 143. Google Scholar 13 : Discovery of urinary biomarkers. Molec Cell Proteom2006; 5: 1760. Google Scholar 14 : Urinary excretion of creatinine in normal subjects. Chin Pharmaceut J1992; 44: 235. Google Scholar 15 : Estimation of the Youden Index and its associated cutoff point. Biom J2005; 47: 458. Google Scholar 16 : Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A2011; 108: 14813. Google Scholar 17 : Apolipoprotein E inhibits serum-stimulated cell proliferation and enhances serum-independent cell proliferation. J Biol Chem2001; 276: 43455. Google Scholar 18 : Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet2000; 1: 507. Google Scholar 19 : The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression. DNA Cell Biol2011; 30: 851. Google Scholar 20 : An interaction between apolipoprotein E and TERE1 with a possible association with bladder tumor formation. J Cell Biochem2005; 95: 419. Google Scholar 21 : Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics2012; 12: 135. Google Scholar 22 : Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab2010; 99: 157. Google Scholar 23 : Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta2009; 404: 111. Google Scholar 24 : Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis2010; 27: 55. Google Scholar 25 : Spotlight on differentially expressed genes in urinary bladder cancer. PLoS One2011; 6: e18255. Google Scholar 26 : Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol2011; 29: 703. Google Scholar 27 : Interleukin-1-inducible genes in endothelial cells: Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem1992; 267: 22190. Google Scholar 28 : Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res2011; 17: 2395. Google Scholar 29 : Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer2011; 18: 465. Google Scholar 30 : Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol2009; 9: 12. Google Scholar © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAndersson K (2018) This Month in Investigative UrologyJournal of Urology, VOL. 188, NO. 6, (2033-2034), Online publication date: 1-Dec-2012. Volume 188Issue 6December 2012Page: 2377-2383 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Keywordsurinary bladderurinary bladder neoplasmsalpha 1-antitrypsinapolipoproteins AdiagnosisMetricsAuthor Information Virginia Urquidi Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience. More articles by this author Steve Goodison Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience. More articles by this author Shanti Ross Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida More articles by this author Myron Chang Department of Biostatistics, University of Florida, Gainesville, Florida More articles by this author Yunfeng Dai Department of Biostatistics, University of Florida, Gainesville, Florida More articles by this author Charles J. Rosser Section of Urologic Oncology, M.D. Anderson Cancer Center Orlando, Orlando, Florida Financial interest and/or other relationship with Nonagen Bioscience, Endocare and the Department of Defense. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2113018780 created "2016-06-24" @default.
• W2113018780 creator A5003347451 @default.
• W2113018780 creator A5013769942 @default.
• W2113018780 creator A5024594616 @default.
• W2113018780 creator A5027364145 @default.
• W2113018780 creator A5035438292 @default.
• W2113018780 creator A5040870373 @default.
• W2113018780 date "2012-12-01" @default.
• W2113018780 modified "2023-10-02" @default.
• W2113018780 title "Diagnostic Potential of Urinary α1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer" @default.
• W2113018780 cites W1537516218 @default.
• W2113018780 cites W1981498432 @default.
• W2113018780 cites W1989995470 @default.
• W2113018780 cites W1990016625 @default.
• W2113018780 cites W1998520443 @default.
• W2113018780 cites W2000338102 @default.
• W2113018780 cites W2003103844 @default.
• W2113018780 cites W2003477758 @default.
• W2113018780 cites W2022988499 @default.
• W2113018780 cites W2042060775 @default.
• W2113018780 cites W2044403560 @default.
• W2113018780 cites W2053900432 @default.
• W2113018780 cites W2054808769 @default.
• W2113018780 cites W2059561965 @default.
• W2113018780 cites W2086811043 @default.
• W2113018780 cites W2094422890 @default.
• W2113018780 cites W2103346522 @default.
• W2113018780 cites W2121101037 @default.
• W2113018780 cites W2126547970 @default.
• W2113018780 cites W2128580887 @default.
• W2113018780 cites W2130658314 @default.
• W2113018780 cites W2142198156 @default.
• W2113018780 cites W2147439971 @default.
• W2113018780 cites W2148342716 @default.
• W2113018780 cites W2150780222 @default.
• W2113018780 cites W2153861174 @default.
• W2113018780 cites W2165948908 @default.
• W2113018780 cites W82321444 @default.
• W2113018780 doi "https://doi.org/10.1016/j.juro.2012.07.094" @default.
• W2113018780 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4013779" @default.
• W2113018780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23321582" @default.
• W2113018780 hasPublicationYear "2012" @default.
• W2113018780 type Work @default.
• W2113018780 sameAs 2113018780 @default.
• W2113018780 citedByCount "33" @default.
• W2113018780 countsByYear W21130187802012 @default.
• W2113018780 countsByYear W21130187802013 @default.
• W2113018780 countsByYear W21130187802014 @default.
• W2113018780 countsByYear W21130187802015 @default.
• W2113018780 countsByYear W21130187802016 @default.
• W2113018780 countsByYear W21130187802018 @default.
• W2113018780 countsByYear W21130187802019 @default.
• W2113018780 countsByYear W21130187802021 @default.
• W2113018780 countsByYear W21130187802022 @default.
• W2113018780 countsByYear W21130187802023 @default.
• W2113018780 crossrefType "journal-article" @default.
• W2113018780 hasAuthorship W2113018780A5003347451 @default.
• W2113018780 hasAuthorship W2113018780A5013769942 @default.
• W2113018780 hasAuthorship W2113018780A5024594616 @default.
• W2113018780 hasAuthorship W2113018780A5027364145 @default.
• W2113018780 hasAuthorship W2113018780A5035438292 @default.
• W2113018780 hasAuthorship W2113018780A5040870373 @default.
• W2113018780 hasBestOaLocation W21130187802 @default.
• W2113018780 hasConcept C121608353 @default.
• W2113018780 hasConcept C126322002 @default.
• W2113018780 hasConcept C126894567 @default.
• W2113018780 hasConcept C142724271 @default.
• W2113018780 hasConcept C2779134260 @default.
• W2113018780 hasConcept C2779762690 @default.
• W2113018780 hasConcept C2780352672 @default.
• W2113018780 hasConcept C2908931861 @default.
• W2113018780 hasConcept C57089818 @default.
• W2113018780 hasConcept C71924100 @default.
• W2113018780 hasConcept C77411442 @default.
• W2113018780 hasConceptScore W2113018780C121608353 @default.
• W2113018780 hasConceptScore W2113018780C126322002 @default.
• W2113018780 hasConceptScore W2113018780C126894567 @default.
• W2113018780 hasConceptScore W2113018780C142724271 @default.
• W2113018780 hasConceptScore W2113018780C2779134260 @default.
• W2113018780 hasConceptScore W2113018780C2779762690 @default.
• W2113018780 hasConceptScore W2113018780C2780352672 @default.
• W2113018780 hasConceptScore W2113018780C2908931861 @default.
• W2113018780 hasConceptScore W2113018780C57089818 @default.
• W2113018780 hasConceptScore W2113018780C71924100 @default.
• W2113018780 hasConceptScore W2113018780C77411442 @default.
• W2113018780 hasIssue "6" @default.
• W2113018780 hasLocation W21130187801 @default.
• W2113018780 hasLocation W21130187802 @default.
• W2113018780 hasLocation W21130187803 @default.
• W2113018780 hasLocation W21130187804 @default.
• W2113018780 hasOpenAccess W2113018780 @default.
• W2113018780 hasPrimaryLocation W21130187801 @default.
• W2113018780 hasRelatedWork W2010561882 @default.
• W2113018780 hasRelatedWork W2120561004 @default.
• W2113018780 hasRelatedWork W2381010098 @default.
• W2113018780 hasRelatedWork W2421535539 @default.
• W2113018780 hasRelatedWork W2433727248 @default.

• next